ONCY Oncolytics Biotech Inc
Company Analysis
Latest News
🔴 Oncolytics Biotech is trading 5% down — no confirmed catalyst
Oncolytics Biotech is trading 5.39% down at $0.60 on October 5, 2026; no confirmed catalyst has emerged. - No clear company-specific announcement explaining...
🔴 Oncolytics Biotech is trading 5% down; no clear catalyst identified
Oncolytics Biotech is trading 5.28% lower at $0.63; no clear company-specific catalyst for the October 1 decline has been identified. - The latest company...
Oncolytics Reports Accelerating Enrollment in Colorectal Cancer Trial, Interim Data Expected by Year-End
Oncolytics Biotech Inc. announced accelerating patient enrollment for its randomized REO 033 study evaluating its lead drug, pelareorep, in second-line...
🟢 Oncolytics Biotech is trading 5% up with no identified catalyst
Oncolytics Biotech is trading at $0.72, up 5.08% on September 28, 2026; no clearly documented catalyst for the intraday gain surfaced in available search...
🟢 Oncolytics Biotech is trading 5.81% up in pre-market amid broader biotech strength
Oncolytics Biotech is trading at $0.72, up 5.81% now in pre-market, aligned with broader biotechnology strength; no new company-specific catalyst was...
🔴 Oncolytics Biotech is trading 5% down today with no confirmed company-specific catalyst
Oncolytics Biotech is trading 5% lower at $0.68, with the decline appearing to reflect stock-specific selling; no confirmed company-specific catalyst has been...
🔴 Oncolytics Biotech is trading 5.9% down today amid unexplained selling
Oncolytics Biotech is trading 5.9% down at $0.72, reflecting unexplained selling; no clear company-specific catalyst was identified for September 22, 2026. -...
🟢 Oncolytics Biotech is trading 6.92% up today after rebounding from September 11’s $0.75 close
Oncolytics Biotech is trading 6.92% up at $0.80 after rebounding from the $0.75 close on September 11, 2026. - No clear company-specific catalyst has been...
🟢 Oncolytics Biotech is trading 6.75% up today — no clear company-specific catalyst identified
Oncolytics Biotech is trading 6.75% up at $0.80, with no clear company-specific catalyst identified for the September 14 move. - The move reverses its recent...
🟢 Oncolytics Biotech is trading 5.94% up today with no clear company-specific catalyst identified
Oncolytics Biotech is trading 5.94% up at $0.79, with no clear company-specific catalyst identified for September 14, 2026. - The latest announcement, dated...
🟢 Oncolytics Biotech is trading 5.77% up today — no clear catalyst identified
Oncolytics Biotech is trading 5.77% up at $0.79, with no clear company-specific catalyst identified for September 14, 2026. - The September 10 announcement...
🟢 Oncolytics Biotech is trading 6% up in pre-market with no clear company-specific catalyst
Oncolytics Biotech is trading 5.97% up at $0.79, based on the provided pre-market quote; no clear September 14, 2026 company-specific catalyst was...
🔴 Oncolytics Biotech is trading 5% down today with no clear catalyst
Oncolytics Biotech is trading 5% down at $0.80, with no clear company-specific catalyst identified for September 8, 2026. - The broader market is also weaker:...
🟢 Oncolytics Biotech is trading 5% up today as XBI rises 2.75%
Oncolytics Biotech is trading at $0.88, up 5.02%, with biotech-sector momentum the likeliest driver. • No fresh company-specific announcement was identified...
🟢 Oncolytics Biotech is trading 5.4% up today amid broader biotech-sector gains
Oncolytics Biotech is trading 5.4% up at $0.84, with the move most consistent with broader risk appetite. - Biotechnology is up 2.02%, while major U.S....
Oncolytics Aligns with FDA on Pivotal Study Design for Colorectal Cancer Drug
Oncolytics Biotech announced it received written feedback from the U.S. Food and Drug Administration (FDA) aligning on a registrational path for its drug,...
🟢 Oncolytics Biotech is trading 5.67% up today after investors digested second-quarter results
Oncolytics Biotech is trading 5.67% up now at $0.85 after investors digested its second-quarter results, published August 12, 2026. - Reported a $9.44 million...
Oncolytics Biotech Inc Q2 2026 Earnings Preview: What Analysts Expect on August 14, 2026
For the second quarter of 2026, analysts expect Oncolytics Biotech to report an EPS of -$0.06 on zero revenue, with the current $1.45 share price trading...
🔴 Oncolytics Biotech is trading 5% down today
Oncolytics Biotech is trading 5.13% down at $0.76 after no clear company-specific catalyst emerged for the August 10, 2026 decline. - July’s FDA Fast Track...
🟢 Oncolytics Biotech is trading 5.8% up today amid a broad biotech sector and market rally
Oncolytics Biotech is trading 5.8% up at $0.82 amid a strong risk-on session in U.S. equities and a broad biotech sector rally. • The move aligns with a wider...